BR112015022538A2 - terapia de indução de rituximab seguida por terapia de acetato de glatirâmero - Google Patents

terapia de indução de rituximab seguida por terapia de acetato de glatirâmero

Info

Publication number
BR112015022538A2
BR112015022538A2 BR112015022538A BR112015022538A BR112015022538A2 BR 112015022538 A2 BR112015022538 A2 BR 112015022538A2 BR 112015022538 A BR112015022538 A BR 112015022538A BR 112015022538 A BR112015022538 A BR 112015022538A BR 112015022538 A2 BR112015022538 A2 BR 112015022538A2
Authority
BR
Brazil
Prior art keywords
therapy
followed
subject
glatiramer acetate
rituximab
Prior art date
Application number
BR112015022538A
Other languages
English (en)
Inventor
Vollmer Timothy
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51527961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015022538(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR112015022538A2 publication Critical patent/BR112015022538A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

resumo “terapia de indução de rituximab seguida por terapia de acetato de glatirâmero” a presente invenção proporciona um método de tratamento de um sujeito afligido com uma forma de esclerose múltipla ou apresentando uma síndrome clinicamente isolada compreendendo a administração periódica de uma quantidade de um anticorpo anti-cd20, pelo menos, duas vezes ao sujeito seguido por administração periódica de uma quantidade de glatirâmero de etilo para o sujeito, em que as quantidades são eficazes para tratar o sujeito.
BR112015022538A 2013-03-12 2014-03-12 terapia de indução de rituximab seguida por terapia de acetato de glatirâmero BR112015022538A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778016P 2013-03-12 2013-03-12
PCT/US2014/025075 WO2014165280A1 (en) 2013-03-12 2014-03-12 Rituximab induction therapy followed by glatiramer acetate therapy

Publications (1)

Publication Number Publication Date
BR112015022538A2 true BR112015022538A2 (pt) 2017-07-18

Family

ID=51527961

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022538A BR112015022538A2 (pt) 2013-03-12 2014-03-12 terapia de indução de rituximab seguida por terapia de acetato de glatirâmero

Country Status (18)

Country Link
US (3) US20160022811A1 (pt)
EP (1) EP2968559A4 (pt)
JP (1) JP2016512552A (pt)
KR (1) KR20150138240A (pt)
CN (1) CN105188751A (pt)
AR (1) AR095372A1 (pt)
AU (1) AU2014248524A1 (pt)
BR (1) BR112015022538A2 (pt)
CA (1) CA2903127A1 (pt)
CL (1) CL2015002597A1 (pt)
EA (1) EA201591687A1 (pt)
HK (2) HK1218253A1 (pt)
IL (1) IL240355A0 (pt)
MX (1) MX2015012156A (pt)
PE (1) PE20151937A1 (pt)
TW (1) TW201521757A (pt)
WO (1) WO2014165280A1 (pt)
ZA (1) ZA201507489B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2630962T (pt) 2009-08-20 2018-08-01 Yeda Res & Development Company Ltd Terapia de acetato de glatirâmero de baixa frequência
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
AU2012323345A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US9744920B2 (en) * 2015-04-21 2017-08-29 Mazda Motor Corporation Noise insulation structure of cabin floor
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
WO2019110643A1 (en) * 2017-12-05 2019-06-13 Mabion Sa Combination therapy of multiple sclerosis comprising a cd20 ligand
US11814439B1 (en) * 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR049200A1 (es) * 2004-06-04 2006-07-05 Genentech Inc Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20
US20070161566A1 (en) * 2006-01-11 2007-07-12 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011086470A1 (en) * 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis
EP2667888A4 (en) * 2011-01-28 2015-11-11 Univ Oregon Health & Science LIGMPHES OF RECOMBINANT T LYMPHOCYTES AND ANTIBODIES BINDING TO LYMPHOCYTES B FOR THE TREATMENT OF AUTOIMMUNE DISEASES

Also Published As

Publication number Publication date
TW201521757A (zh) 2015-06-16
US20140271630A1 (en) 2014-09-18
CA2903127A1 (en) 2014-10-09
EA201591687A1 (ru) 2016-07-29
AU2014248524A1 (en) 2015-10-29
EP2968559A1 (en) 2016-01-20
US20160022811A1 (en) 2016-01-28
JP2016512552A (ja) 2016-04-28
MX2015012156A (es) 2015-11-30
AR095372A1 (es) 2015-10-14
US20170143824A1 (en) 2017-05-25
WO2014165280A1 (en) 2014-10-09
HK1218253A1 (zh) 2017-02-10
ZA201507489B (en) 2017-01-25
CL2015002597A1 (es) 2016-04-15
HK1219413A1 (zh) 2017-04-07
EP2968559A4 (en) 2016-11-02
IL240355A0 (en) 2015-09-24
KR20150138240A (ko) 2015-12-09
PE20151937A1 (es) 2016-01-15
CN105188751A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
BR112015022538A2 (pt) terapia de indução de rituximab seguida por terapia de acetato de glatirâmero
BR112015022197A2 (pt) tratamento de cataplexia
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
EA201490748A1 (ru) Лечение рассеянного склероза комбинацией лахинимода и финголимода
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112017003571A2 (pt) terapia combinada
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
BR112013006673A2 (pt) produtos terapêuticos para câncer de mama
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
BR112015026292A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112015033069A2 (pt) moduladores de receptor do hormônio de crescimento
WO2018039475A8 (en) Use of pridopidine for treating dystonias
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112014011223A2 (pt) método de tratar uma doença proliferativa
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
BR112012008310A2 (pt) métodos para tratamento de tumores cerebrais
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
BR112014006473A2 (pt) composição e método para tratamento de uma doença autoimune
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
BR112015009602A2 (pt) análogos quiméricos de somatostatina-dopamina
BR112018002763A2 (pt) método para cicatrização de ferimentos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]